Targeting conserved TIM3 + VISTA + tumor-associated macrophages overcomes resistance to cancer immunotherapy
Science Advances · 19.07.2024 · 10 (29)
DOI: 10.1126/sciadv.adm8660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 19.07.2024. Verfasst von Isaure Vanmeerbeek und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell Stress and Immunity, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Tumor-Associated Macrophages, Hepatitis A Virus Cellular Receptor 2, Immunotherapy. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Despite the success of immunotherapy, overcoming immunoresistance in cancer remains challenging. We identified a unique niche of tumor-associated macrophages (TAMs), coexpressing T cell immunoglobulin and mucin domain–containing 3 (TIM3) and V-domain immunoglobulin suppressor of T cell activation (VISTA), that dominated human and mouse tumors resistant to most of the currently used immunotherapies. TIM3 + VISTA + TAMs were sustained by IL-4–enriching tumors with low (neo)antigenic and T cell–depleted features. TIM3 + VISTA + TAMs showed an anti-inflammatory and protumorigenic phenotype coupled with inability to sense type I interferon (IFN). This was established with cancer cells succumbing to immunogenic cell death (ICD). Dying cancer cells not only triggered autocrine type I IFNs but also exposed HMGB1/VISTA that engaged TIM3/VISTA on TAMs to suppress paracrine IFN-responses. Accordingly, TIM3/VISTA blockade synergized with paclitaxel, an ICD-inducing chemotherapy, to repolarize TIM3 + VISTA + TAMs to proinflammatory TAMs that killed cancer cells via tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) signaling. We propose targeting TIM3 + VISTA + TAMs to overcome immunoresistant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Cell Stress and Immunity, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
- Laboratory of Tumour Inflammation and Angiogenesis, VIB Center for Cancer Biology, Leuven, Belgium.
- Laboratory of Tumour Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.
- Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven, Rega Institute, Leuven, Belgium.
- JJP Biologics, Warsaw, Poland.
- Laboratory of Adaptive Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
ORCID-Profile: Isaure Vanmeerbeek, Stefan Naulaerts, Jenny Sprooten, Raquel S Laureano, Rosa Trotta, Shikang Zhao, Joren Verelst, Maarten Jacquemyn, Martyna Pociupany, Louis Boon, Susan M Schlenner, Sabine Tejpar, Dirk Daelemans, Massimiliano Mazzone, Abhishek D Garg
Zitieren
APA
Vanmeerbeek, I., Naulaerts, S., Sprooten, J., Laureano, R. S., Govaerts, J., Trotta, R., Pretto, S., Zhao, S., Cafarello, S. T., Verelst, J., Jacquemyn, M., Pociupany, M., Boon, L., Schlenner, S. M., Tejpar, S., Daelemans, D., Mazzone, M., & Garg, A. D. (2024). Targeting conserved TIM3 + VISTA + tumor-associated macrophages overcomes resistance to cancer immunotherapy. Science Advances, 10(29). https://doi.org/10.1126/sciadv.adm8660
Vancouver
Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano RS, Govaerts J, Trotta R, et al. Targeting conserved TIM3 + VISTA + tumor-associated macrophages overcomes resistance to cancer immunotherapy. Science Advances. 2024;10(29). doi:10.1126/sciadv.adm8660
BibTeX
@article{Vanmeerbeek2024,
author = {Vanmeerbeek, Isaure and Naulaerts, Stefan and Sprooten, Jenny and Laureano, Raquel S and Govaerts, Jannes and Trotta, Rosa and Pretto, Samantha and Zhao, Shikang and Cafarello, Sarah Trusso and Verelst, Joren and Jacquemyn, Maarten and Pociupany, Martyna and Boon, Louis and Schlenner, Susan M and Tejpar, Sabine and Daelemans, Dirk and Mazzone, Massimiliano and Garg, Abhishek D},
title = {Targeting conserved TIM3 + VISTA + tumor-associated macrophages overcomes resistance to cancer immunotherapy},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {29},
doi = {10.1126/sciadv.adm8660}
}
EUVIMED